ACC.17

Episodes 1-16 of 19

Troponin is an independent predictor of CV events at non-cardiac surgery
Troponin is an independent predictor of CV events at non-cardiac surgery
ACC.17
Troponin is an independent predictor of CV events at non-cardiac surgery
- Dr. P.J. Devereaux
E-counselling improves adherence in hypertensives
E-counselling improves adherence in hypertensives
ACC.17
E-counselling improves adherence in hypertensives
- Dr. Rob Nolan
PCI-registry-based trial shows that IFR is non-inferior to FFR, with reduced discomfort and stenting
PCI-registry-based trial shows that IFR is non-inferior to FFR, with reduced discomfort and stenting
ACC.17
PCI-registry-based trial shows that IFR is non-inferior to FFR, with reduced discomfort and stenting
Initiating digoxin in AF patients associated with early hazard of sudden death
Initiating digoxin in AF patients associated with early hazard of sudden death
ACC.17
Initiating digoxin in AF patients associated with early hazard of sudden death
- Dr. Renato Lopes
LDL lowering for CVD prevention: From hypothesis to axiom
LDL lowering for CVD prevention: From hypothesis to axiom
ACC.17
LDL lowering for CVD prevention: From hypothesis to axiom
- Prof. John JP Kastelein
The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials
The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials
ACC.17
The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials
- Prof. Stephen J. Nicholls
PCSK9 outcome trials: The results put into perspective of other clinical developments
PCSK9 outcome trials: The results put into perspective of other clinical developments
ACC.17
PCSK9 outcome trials: The results put into perspective of other clinical developments
- Prof. Peter Sever
Identification of patients who will benefit is important after FOURIER
Identification of patients who will benefit is important after FOURIER
ACC.17
Identification of patients who will benefit is important after FOURIER
- Prof. Ulf Landmesser
The implications of PCSK9 outcome trials for GPs
The implications of PCSK9 outcome trials for GPs
ACC.17
The implications of PCSK9 outcome trials for GPs
- Prof. Richard Hobbs, MD
Landmark study with PCSK9 inhibitor will change clinical practice
Landmark study with PCSK9 inhibitor will change clinical practice
ACC.17
Landmark study with PCSK9 inhibitor will change clinical practice
- Prof. Eric Bruckert
Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?
Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?
ACC.17
Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?
- Prof. John Chapman
Changing therapeutic behaviour after FOURIER
Changing therapeutic behaviour after FOURIER
ACC.17
Changing therapeutic behaviour after FOURIER
- Prof. Wolfgang Koenig
Factor Xa inhibitor vs. aspirin in extended phase of prevention recurrent VTE
Factor Xa inhibitor vs. aspirin in extended phase of prevention recurrent VTE
ACC.17
Factor Xa inhibitor vs. aspirin in extended phase of prevention recurrent VTE
- Dr. Philip S. Wells
No J-shaped curve for efficacy in PCSK9 outcome trials
No J-shaped curve for efficacy in PCSK9 outcome trials
ACC.17
No J-shaped curve for efficacy in PCSK9 outcome trials
- Prof Kausik Ray
Lowering LDL-c for a longer period of time really matters
Lowering LDL-c for a longer period of time really matters
ACC.17
Lowering LDL-c for a longer period of time really matters
PCSK9 inhibition works, but you can’t force biology
PCSK9 inhibition works, but you can’t force biology
ACC.17
PCSK9 inhibition works, but you can’t force biology
- Prof. Wouter Jukema

1/2

Episodes 1-16 of 19

Title

Share on ReachMD